Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Profit After Tax (2016 - 2026)

Aytu Biopharma has reported Profit After Tax over the past 15 years, most recently at -$10.6 million for Q4 2025.

  • Quarterly Profit After Tax fell 1691.58% to -$10.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$23.9 million through Dec 2025, down 478.89% year-over-year, with the annual reading at -$13.6 million for FY2025, 8.32% down from the prior year.
  • Profit After Tax was -$10.6 million for Q4 2025 at Aytu Biopharma, down from $2.0 million in the prior quarter.
  • Over five years, Profit After Tax peaked at $4.0 million in Q1 2025 and troughed at -$53.3 million in Q1 2022.
  • The 5-year median for Profit After Tax is -$6.7 million (2022), against an average of -$9.5 million.
  • Year-over-year, Profit After Tax soared 402.27% in 2024 and then crashed 1691.58% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$11.5 million in 2021, then soared by 42.04% to -$6.7 million in 2022, then skyrocketed by 96.71% to -$220000.0 in 2023, then soared by 402.27% to $665000.0 in 2024, then crashed by 1691.58% to -$10.6 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Profit After Tax are -$10.6 million (Q4 2025), $2.0 million (Q3 2025), and -$19.3 million (Q2 2025).